# Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

> **NCT02264990** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 595 (actual)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Veliparib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02264990
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-30
- **Primary completion:** 2019-11-14
- **Final completion:** 2020-02-21
- **Target enrollment:** 595 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264990, "Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02264990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*